Macrogenics Profit Margin

Macrogenics (MGNX) currently reports a profit margin of -8.7% as of June 2026. That compares with -22.21% in the prior-year period — up 60.8% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Macrogenics's profit margin history and peer comparisons.

Macrogenics's profit margin increased from -22.21% to -8.7% — a 60.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Macrogenics's profit margin of -8.7% is lower than the Healthcare sector average of 21.34%. That is roughly 140.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Macrogenics's current -8.7% should be judged against Healthcare norms (sector average: 21.34%) and against MGNX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -8.7%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Macrogenics, and consider following MGNX for alerts when major investors trade the stock.